Clinical Trial Search

Primary: Number of Patients With Solitary Elective Volume Recurrence — 0 Participants

Primary: Improvement in Neck Fibrosis — 13; 13 participants

Primary: Llocoregional Recurrence — 27 Participants

Primary: Feasibility of TFRT Planning and Delivery Defined by Number of Participants Starting Radiotherapy Within 15 Days of Simulation — 4 Participants

Primary: 1-year Local Progression-free Survival (PFS) — 60 percentage of participants

Primary: Percentage of Participants With Grade 0-1 Observer-rated Dysphagia — 94 percentage of participants

Primary: Local Control Rate — 1; 5 Participants

Primary: Risk of Solitary Elective Volume Recurrence Following Elective Volume Reduction Using INRT — 11; 9; 3; 6 percentage of participants

Primary: Duration of Local Control — 4.6 number of months to local failure

Primary: 1-year Local Control — NA; NA months

Primary: Maximum-tolerated Radiation Dose — 32.5 Gy

Primary: Assess the Safety of the Study Drug by Calculating the Proportion of Patients Who Experience Grade 4 or 5 Study Drug Related Adverse Events, as Assessed by CTCAE v 4.03…

Primary: Percentage of Participants With Local Regional Control — 91.1 percentage of subjects

Primary: Number of Participants With Adverse Events (AEs) — 2; 3; 0; 2 participants

Primary: Feasibility of the LEF-SCP (Self-Care Skill Training Sessions) — 20; 18 Participants

Primary: Incidence of Dose-Limiting Toxicities at 50 Gy With Concurrent Atezolizumab — 2; 0; 0; 0 Participants

Primary: Grade of Xerostomia — 1.14; 1.17 units on a scale

Primary: Progression-free Survival (PFS) Rate — 50; 43; 110; 117 Participants — p=0.83

Primary: Evaluate the Tumor Shrinkage (%) to Measure the Deep Response Rate (DRR) — 25; 26; 0 Participants

Primary: Relapse Free Survival — 30; 28 participants

Primary: Toxicity — 0; 1; 2 participants

Primary: Number of Participants With Progression-Free Survival (PFS) — 27 Participants

Primary: Acute Radiation Effects (Less Than 90 Days Post Treatment) — 0 Participants

Primary: Overall Progression-Free Survival (PFS). — 370 Days

Primary: Incidence of Treatment Related Adverse Events — 4; 2; 4; 1 Participants

Primary: 20 Week Progression Free Survival Rate — 0.90 proportion of participants

Primary: Progression-free Survival at 2 Years — 75.9 percentage of participants

Primary: Subjective, Objective, Management, and Analytic (SOMA) Score — 1.59; 1.0 units on a scale

Primary: Grade 3 or Higher Adverse Events — 9 Participants

Primary: Overall Survival (Percentage of Participants Alive) — 64.3; 70.3 percentage of patients — p=0.180